Brief: Ascentage Pharma Group International Says China's Nmpa Accepted & Granted Priority Review Designation To NDA For Olverembatinib
19/07/2022 11:17
July 19 (Reuters) - Ascentage Pharma Group International
6855.HK :
* CHINA'S NMPA ACCEPTED & GRANTED PRIORITY REVIEW
DESIGNATION TO
NDA FOR OLVEREMBATINIB
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up